ASH – 2023 – Poster Presentation – 4862
Publications
December 11, 2023
Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation
VCAR33
Presented by: Nirali N. Shah, MD, MHSc – National Cancer Institute | National Institutes of Health